Summary
The effects of torasemide have been studied in 7 healthy controls and 9 patients with stable chronic renal failure of various degrees.
After a control period of 3 days torasemide 20 mg i. v. caused a dramatic increase in diuresis and electrolyte excretion without affecting the glomerular filtration rate. The duration of action of torasemide, τ, averaged 6 h and was independent of the creatinine clearance, CLCR. When related to τ the drug-induced excretion of Cl−, Na+, K+, Ca2+ and Mg2+ showed strong linear dependence on CLCR. Both the kaliuresis and the calciuresis during τ were tightly correlated with the natriuresis over the broad range of CLCR. Similarly, the excretion of Mg2+ was dependent on the kaliuresis.
The torasemide-induced kaliuresis amounted to 12% of natriuresis, as after furosemide. The kaliuretic effect of loop diuretics is smaller than that of the thiazides. After τ, e. g. over a 24 h period, kaliuresis was not correlated with natriuresis. The magnitude of the rebound effect was diminished with increasing renal impairment.
Similar content being viewed by others
References
Wittner M, Di Stefano A, Schlatter E, Delarge J, Greger G (1986) Torasemide inhibits NaCl reabsorption in the thick ascending limb of the loop of Henle. Pflügers Arch 407: 611–614
Delarge J, Lapière C (1974) Synthèse et propriétés pharmacologiques des quelques N-acylsulfonamides. Ann Pharm Fr 32: 657–667
Delarge J, Lapière C (1978) Une nouvelle classe de diurétiques “high ceiling”, dérivés de l'alkyl-1 (phenylamino-4-pyridyl-3-sulfonyl)-3 urée. Ann Pharm Fr 36: 369–380
Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS (1986) Diuretic activity of torasemide and furosemide in chronic heart failure: A comparative double blind cross-over study. Eur J Clin Pharmacol 31 [Suppl]: 35–42
Spannbrucker N, Achhammer I, Metz P, Glocke M (1988) Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneim-Forsch/Drug Res 38 (I): 190–193
Dodion L, Willems JL (1986) Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency. Eur J Clin Pharmacol 32 [Suppl]: 49–51
Klütsch K, Großwendt J, Haecker W (1988) Single dose comparison of torasemide and furosemide in patients with advanced renal failure. Arzneim-Forsch/Drug-Res 38 (I): 200–204
Breslau N, Moses AM, Weiner JM (1976) The role of volume contraction in the hypocalciuric action of chlorothiazide. Kidney Int 10: 164–170
Brater DC, Leinfelder J, Anderson SA (1987) Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 42: 187–192
Brater DC, Anderson SA, Brown-Cartwright D (1986) Response to furosemide in chronic renal insufficiency: Rationale for limited dose. Clin Pharmacol Ther 40: 134–139
Gerber JG (1981) Antihypertensive agents and diuretics. In: Anderson RJ, Schrier Rw (Eds) Clinical use of drugs in patients with kidney and liver disease. Saunders, London, pp 211–229
Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20: 27–33
Knauf H, Mutschler E (1990) The Na load in the nephron segment determines the ceiling qualitiy of a diuretic. In: JB Puschett, editor. Diuretics III, Chemistry, Pharmacology and Clinical Applications. Elsevier, New York, pp 359–362
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J (1988) Peripheral arterial vasodilation hypothesis. A proposal for the initiation or renal sodium and water retention in cirrhosis. Hepatol 8: 1115–1157
Brater DC, Chennavasin P, Seiwell R (1980) Furosemide in patients with heart failure: Shift in dose-response curves. Clin Pharmacol Ther 28: 182–186
Keller E, Hoppe-Seyler G, Schollmeyer P (1982) Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin Pharmacol Ther 32: 442–449
Skorecki KL, Brenner BM (1982) Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med 72: 323–337
Epstein M (1988) Renal sodium handling in liver disease. In: Epstein M (editor). The kidney in liver disease, 3. ed. Williams and Wilkins, Baltimore, pp 3–30
Fine LG, Sakhrani LM (1983) Toward a physiological definition of the hepatorenal syndrome. In: Epstein M (editor). The kidney in liver disease, 3. ed. Williams and Wilkins, Baltimore, pp 107–111
Schrier RW (1988) Pathogenesis of sodium and water retention in high and low output cardiac failure, cirrhosis, nephrotic syndrome and pregnancy. N Engl J Med 319: 1065–1072
Knauf H, Wenk E, Schölmerich J, Georg KJ, Gerok W, Leser HG, Mutschler E (1990) Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion. Klin Wochenschr, 68: 545–551
Bricker NS (1982) Sodium homeostasis in chronic renal disease. Kidney Int 21: 886–897
Lesne M, Clerckx-Braun F, Duhoux P, Van Ypersele de Strihou C (1982) Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. Int J Clin Pharmacol Ther Toxicol 20: 382–387
Neugebauer G, Besenfelder E, von Möllendorff E (1988) Pharmacokinetics and metabolism of torasemide in man. Arzneim-Forsch/Drug Res 38 (I): 164–166
Spahn H, Knauf H, Mutschler E (1990) Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. Eur J Clin Pharmacol 39: 345–348
Knauf H, Liebig R, Schollmeyer P, Rosenthal J, Kölle EK, Mutschler E (1984) Pharmacodynamics and kinetics of etozolin/ozolinone in hypertensive patients with normal and impaired kidney function. Eur J Pharmacol 26: 687–693
Thurau K (1977) Diuretics and tubuloglomerular feedback regulation of GFR. In: Siegenthaler W, Beckerhoff R, Wetter W (eds) Diuretics in research and clinics. Thieme, Stuttgart, pp 43–50
Schlatter E, Salomonsson M, Person AEG, Greger R (1990) Macula densa cells reabsorb NaCl via furosemide-sensitive Na+:K+:2Cl cotransport. In: Puschett JB (ed). Diuretics III, chemistry, pharmacology and clinical applications. Elsevier, New York, pp 756–758
Schnermann J, Briggs P (1985) Function of the juxtaglomerular apparatus: Local control of glomerular hemodynamics. In: Seldin D, Giebisch G (eds) The kidney: physiology and pathophysiology. Raven, New York, pp 669–697
Greger R, Schlatter E (1983) Cellular mechanism of the action of loop diuretics on the thick ascending limb of Henle's loop. Klin Wochenschr 61: 1019–1027
Wright F, Giebisch G (1985) Regulation of potassium excretion. In: Seldin D, Giebisch G (eds) The kidney: physiology and pathophysiology. Raven, New York, pp 1223–1249
Wright F (1986) Renal potassium transport along the nephron. In: Giebisch G (ed) Potassium transport: physiology and pathophysiology. Academic Press, New York
Knauf H, Reuter K, Mutschler E (1985) Limitation on the use of amiloride in early renal failure. Eur J Clin Pharmacol 28: 61–66
Constanzo LS, Windhager EE (1978) Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Physiol 235: F492-F506
Suki WN (1979) Calcium transport in the nephron. Am J Pharmacol 237:F1-F6
Imai M (1978) Calcium transport across the rabbit thick ascending limb of Henle's loop perfused in vitro. Pflügers Arch 374: 255–263
Sutton RAL, Dirks JH (1975) The renal excretion of calcium: A review of micropuncture data. Can J Physiol Pharmacol 53: 979–988
Knauf H, Mutschler E (1984) Pharmacodynamics and pharmacokinetics of xipamide in patients with normal and impaired kidney function. Eur J Pharmacol 26: 513–520
Quamme GA, Dirks JH (1985) Magnesium: cellular and renal exchanges. In: Seldin DW, Giebisch G (eds) The kidney physiology and pathophysiology. Raven, New York, pp 1269–1280
Knauf H, Mutschler E, Pooth R (1990) Piretanide in mild and advanced renal failure: Pharmacodynamics and renal hemodynamics. In: Puschett JB (ed) Diuretics III, chemistry, pharmacology and clinical applications. Elsevier, New York, pp 346–349
Author information
Authors and Affiliations
Additional information
In memory of our colleague and friend U. Wais who left us too early
Rights and permissions
About this article
Cite this article
Knauf, H., Mutschler, E. Saluretic effect of the loop diuretic torasemide in chronic renal failure. Eur J Clin Pharmacol 39, 337–343 (1990). https://doi.org/10.1007/BF00315406
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315406